Citius Pharmaceuticals Inc.

1.78-0.0550-3.01%Vol 3.90M1Y Perf 172.31%
Apr 13th, 2021 14:20 DELAYED
BID1.77 ASK1.78
Open1.81 Previous Close1.83
Pre-Market- After-Market-
 - -%  - -
Target Price
6.00 
Analyst Rating
Strong Buy 1.00
Potential %
240.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap133.05M 
Earnings Rating
Neutral
Price Range Ratio 52W %
50.31 
Earnings Date
13th May 2021

Today's Price Range

1.721.84

52W Range

0.63602.90

5 Year PE Ratio Range

-5.80-2.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.00%
1 Month
-4.19%
3 Months
66.36%
6 Months
71.03%
1 Year
172.31%
3 Years
-39.00%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CTXR1.78-0.0550-3.01
AAPL134.232.99002.28
GOOG2 263.058.26000.37
MSFT257.821.91000.75
XOM55.720.22000.40
WFC39.86-0.9100-2.23
JNJ158.87-2.7700-1.71
FB312.170.63000.20
GE13.46-0.1300-0.96
JPM154.46-1.4900-0.96
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.15-
Q03 2019-0.06-0.20-233.33
Q02 2019-0.20-0.200.00
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.08-133.33Negative
6/2021 QR-0.06-124.00Negative
9/2021 FY-0.34-169.39Negative
9/2022 FY0.31-86.04Negative
Next Report Date13th May 2021
Estimated EPS Next Report-0.08
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume3.91M
Shares Outstanding74.96M
Trades Count9.30K
Dollar Volume36.96M
Avg. Volume13.10M
Avg. Weekly Volume3.83M
Avg. Monthly Volume6.02M
Avg. Quarterly Volume14.73M

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock closed at 1.83 per share at the end of the most recent trading day (a 0.55% change compared to the prior day closing price) with a volume of 4.26M shares and market capitalization of 133.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Citius Pharmaceuticals Inc. CEO is Myron Z. Holubiak.

The one-year performance of Citius Pharmaceuticals Inc. stock is 172.31%, while year-to-date (YTD) performance is 79.41%. CTXR stock has a five-year performance of %. Its 52-week range is between 0.636 and 2.9, which gives CTXR stock a 52-week price range ratio of 50.45%

Citius Pharmaceuticals Inc. currently has a PE ratio of -4.00, a price-to-book (PB) ratio of 9.73, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.38%, a ROC of -88.90% and a ROE of -90.21%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Citius Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. Citius Pharmaceuticals Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Citius Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6, which is +240.19% compared to the current price. The earnings rating for Citius Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Citius Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Citius Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 28.71, ATR14 : 0.24, CCI20 : -63.20, Chaikin Money Flow : -0.10, MACD : 0.13, Money Flow Index : 40.30, ROC : -8.96, RSI : 58.10, STOCH (14,3) : 22.92, STOCH RSI : 0.53, UO : 50.83, Williams %R : -77.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Citius Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.

CEO: Myron Z. Holubiak

Telephone: +1 908 967-6677

Address: 11 Commerce Drive, Cranford 07016, NJ, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

48%52%

Bearish Bullish

64%36%

News

Stocktwits